search

All clinical trials

Results 9931-9940 of 470744

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial...

Endometrial Neoplasm Malignant Stage I

To see if Gonadotropin-releasing hormone analogue (GnRHa) combined with aromatase inhibitors (AIs) will achieve better complete response rate than megestrol acetate or medroxyprogesterone acetate (MA/MPA) alone as fertility-sparing treatment for patients with early endometrial carcinoma.

Recruiting15 enrollment criteria

Conventional-therapy & FES-therapy In-Veritas Effects Study

C5 Palsy

This randomized clinical trial will primarily compare the effectiveness of conventional physiotherapy alone with combined conventional physiotherapy and FES-t along with task-specific training in terms of the improvement of the functional and neurological recovery of patients with persistent C5 palsy.

Recruiting13 enrollment criteria

Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy...

Thyroid CancerPapillary1 more

This project analyzes the relationship between type 2 deiodinase gene polymorphism and the TSH inhibitory treatment efficacy in thyroid cancer patients with thyroidectomy, and explored the factors influencing TSH inhibitory treatment efficacy. It further explores whether patients with diO2-Thr92ALA genotype or DIO2 Orfa-Gly3ASP genotype should choose T4+T3 treatment, and the effect of different treatment options on the quality life of patients.

Recruiting10 enrollment criteria

RAGE Inhibition to Decrease Therapy Cardiotoxicity in Women With Early Breast Cancer

Cancer Related Cognitive DeclineNon-metastatic Breast Cancer

This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy. The Investigators hypothesize that there will be no significant interaction with Azeliragon and chemotherapy and that targeting the RAGE pathway will decrease anthracycline related cardiotoxicity and chemotherapy related cognitive decline.

Recruiting25 enrollment criteria

Broad Band Emission LED Phototherapy Source Versus Narrow Band

Neonatal HyperbilirubinemiaJaundice1 more

Phototherapy is the most frequently used treatment in neonatology when serum bilirubin levels exceed physiological limits. Light-emitting diodes (LEDs) are become routinely used for phototherapy in neonates with hyperbilirubinemia. Blue LED light with peak emission around 460 nm is regarded as the most suitable light sources for phototherapy and they recommended by most neonatal guidelines. However, the effectiveness of phototherapy with narrow-band LED light sources can be increased by expanding the spectral range of incident radiation within the absorption of bilirubin due to the strongly marked heterogeneity absorption properties of bilirubin in a different microenvironment. Longer wavelength light, such as green light, is expected to penetrate the infant's skin deeper. It is still controversial whether the use of green light has any advantage over blue light. The most effective and safest light source and the optimal method to evaluate phototherapy, however, remain unknown.The aim of this study was to compare, at equal light irradiance, the clinical efficacy of broad spectrum blue- green LED with blue narrow spectral band phototherapy device.

Recruiting2 enrollment criteria

ESP Block VS Intrathecal Opioid After Laparoscopic Colorectal Surgery

Surgery

This study is being done to compare 2 types of pain control methods and determine which is more effective postoperatively for laparoscopic colorectal surgery. Group 1 will receive an intrathecal (IT) injection in the back in which a small dose duramorph and bupivacaine will be placed into the spinal fluid. Group 2 will receive an erector spinae plane (ESP) block in which bupivacaine and decadron are injected near the nerves under a muscle in the back.

Recruiting15 enrollment criteria

A Study of HS-20089 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

HS-20089 is a novel DAR-6 antibody-drug conjugate (ADC) targeting B7-H4. In preclinical studies, it inhibited tumor cell growth expressing B7-H4 in vitro and in vivo. The first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-20089 in Patients With Advanced Solid Tumors.

Recruiting20 enrollment criteria

A Study of CM350 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

This is an open label, dose escalation and expansion Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of CM350 in patients with advanced solid tumors. The phase I study consists of a dose escalation part (Part A) and a dose extension part (Part B). The safety and tolerability of CM350 and the maximum tolerated dose (MTD) will be evaluated in Part A. The safety, tolerability and efficacy of CM350 at MTD and/or the dose of one level less than MTD (MTD-1), and the recommended dose level for the phase II study will be determined in Part B.

Recruiting6 enrollment criteria

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute...

Graft Versus Host DiseaseGVHD3 more

This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids

Recruiting12 enrollment criteria

The Effect of Honey on Lessening the Withdrawal Symptoms

Smoking CessationWithdrawal Symptoms

This project investigates the effect of honey on lessening the withdrawal symptoms according to the body constitution.

Recruiting6 enrollment criteria
1...993994995...47075